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TRIBUTYLTIN ALTERS SECRETION OF INTERLEUKIN 1 BETA 
FROM HUMAN IMMUNE CELLS
Shyretha Brown* and Margaret Whalen
*Department of Biological Sciences, Tennessee State University, Nashville, TN, 37209
Department of Chemistry, Tennessee State University, Nashville, TN, 37209
Abstract
Tributyltin (TBT) has been used as a biocide in industrial applications such as wood preservation, 
antifouling paint, and antifungal agents. Due to its many uses, it contaminates the environment and 
has been found in human blood samples. Interleukin 1 beta (IL-1β) is a pro-inflammatory cytokine 
that promotes cell growth, tissue repair, and immune response regulation. Produced predominately 
by both monocytes and macrophages, IL-1β appears to increase the invasiveness of certain tumors. 
This study shows that TBT modifies the secretion of IL-1β from increasingly reconstituted 
preparations of human immune cells. IL-1β secretion was examined after 24h, 48h, or 6 day 
exposures to TBT in highly enriched human NK cells, monocyte-depleted (MD) peripheral blood 
mononuclear cells (MD-PBMCs), PBMCs, granulocytes, and a preparation combining both 
PBMCs and granulocytes (PBMCs+granulocytes). TBT altered IL-1β secretion from all of the 
cells preparations. The 200 nM concentration of TBT normally blocked the secretion of IL-1β, 
while lower concentrations (usually 5-50 nM) elevated secretion of IL-1β. Examination of the 
signaling pathway(s) responsible for the elevated secretion of IL-1β were carried out in MD-
PBMCs. Pathways examined were IL-1β processing (Caspase-1), mitogen-activated protein 
kinases (MAPKs), and nuclear factor kappa B (NFκB). Results indicated that MAPK pathways 
(p44/42 and p38) appear to be the targets of TBT that lead to increased IL-1β secretion from 
immune cells. These results from human immune cells show IL-1β dysregulation by TBT is 
occurring ex vivo. Thus, potential for in vivo effects on pro-inflammatory cytokine levels may 
possibly be a consequence of TBT exposures.
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INTRODUCTION
Interleukin 1 beta (IL-1β) is a cytokine that regulates the inflammatory response and 
promotes cellular growth, and tissue repair (Apte et al., 2006; Arend, 2002; Dinarello, 1996; 
2005; 2009). IL-1β is initially synthesized as a 31-kDa protein that is then processed by 
Caspase-1 to its active form (17-kDa) (Swaan et al., 2001; Dinarello, 1996). The enzyme 
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that proteolytizes IL-1β in monocytes is caspase-1 also referred to as IL-1β converting 
enzyme (ICE) (Kuida et al., 1995; Swaan et al., 2001). Cell types known for producing and 
secreting IL-1β include monocytes, macrophages, T cells, natural killer cells, keratinocytes, 
and fibroblasts (Burger and Dayer, 2002; Dinarello, 2005; Apte et al., 2006; Voronov et al., 
2002). IL-1β appears to also be secreted by neutrophils; however, its processing in 
neutrophils may be independent of Caspase-1 (Guma et al., 2009). Additionally, it has been 
shown that IL-1β can act as a co-stimulator of the production of another pro-inflammatory 
cytokine, interferon gamma (IFNγ), in natural killer (NK) cells (Cooper et al., 2001). This 
pleiotropic cytokine can also contribute to chronic inflammation in some diseases such as 
rheumatoid arthritis and multiple sclerosis (Choy and Panayi, 2001; Lucas and Hohlfeld., 
1995). Additionally, chronic inflammation plays a major role in the development of cancer. 
IL-1β has been detected in human cancers such as breast and pancreatic cancers and 
melanoma (Arlt et al., 2002; Elaraj et al., 2006; Jin et al., 1997; Lewis and Varghese, 2006; 
Muerkoster et al., 2006) and its levels of expression are linked to invasiveness of these 
tumors and are essential for angiogenesis and metastasis (Voronov et al., 2002). Expression 
of IL-1β at the site of tumor development boosts the ability of malignant cells to become 
adhesive and invade neighboring tissues (Chirivi et al., 1996; Vidal-Vanaclocha et al., 
1996). IL-1β can stimulate tumor development as evidenced by studies showing increased 
IL-1β production in human and animal cancer cell lines. These cell lines include ovarian, 
sarcomas, and transitional cell carcinomas. Increased IL-1β production has been associated 
with poor prognoses in patients with breast, colon, and lung cancers as well as melanomas 
(Lewis and Varghese, 2006; Voronov et al., 2002).
Tributyltin (TBT) is an organotin compound that has been used as a biocide in a variety of 
industrial applications such as preservation of wood, controlling of slime in paper mills, 
antifungal agent in industrial cooling water systems and breweries, and antifouling paint 
(Antizar-Ladislao, 2008; Gipperth, 2009; Kannan et al., 1995; Kannan et al., 1997). It is also 
found in some household goods such as siliconized-paper baking parchments and shower 
curtains (Yamada et al., 1993). It is known to contaminate the marine and fresh water 
environment due to common use on boats and ships as an antifouling paint. TBT has been 
banned in the US since 1989 (Loganathan et al., 2001) and by the International Convention 
on the Control of Harmful Antifouling Systems on Ships in 2008 (Gipperth, 2009). 
However, it is still contaminating the environment due to continued application on ships and 
its chemical stability (Gipperth, 2009). TBT is found in fish and other foods (Kannan et al., 
1995); as a result, TBT has been found in human blood samples (ranging as high as 261 nM) 
and other tissues (Antizar-Ladislao, 2008; Kannan et al., 1999; Whalen et al., 1999). 
Mammals with TBT exposure show increased incidences of tumors (Wester et al., 1990). 
TBT decreases the ability of human NK cells to destroy tumor cells with accompanying 
decreases in cytotoxic and cell surface protein expression (Dudimah et al., 2007; Thomas et 
al., 2004; Whalen et al., 2002). In addition, TBT both inhibits and stimulates the secretion of 
tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) from human lymphocytes 
(depending on the exposure concentration) (Hurt et al., 2013; Lawrence et al., 2014). The 
importance of introducing TBT as a stress inducer to the cell environment is to understand 
whether exposure to TBT disrupts normal cellular functions such as immune cell secretion 
of the important regulatory cytokine IL-1β. Based on TBT’s effect on TNFα and IFNγ 
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secretion (Hurt et al., 2013; Lawrence et al., 2014), we hypothesize that exposure to TBT 
will alter the ability of immune cells to secrete IL-1β.
In this study, an array of immune cell preparations were examined for the effects of TBT 
exposures on the secretion of IL-1β. The preparations studied included: human NK cells, 
human monocyte-depleted (MD) peripheral blood mononuclear cells (PBMCs) (MD-
PBMCs), PBMCs, PBMCs combined with granulocytes (PBMCs+granulocytes), and 
granulocytes. The use of increasingly reconstituted immune cell preparation allows us to 
investigate the influence that various immune cell types may have on the ability of TBT to 
induce alteration in secretion of IL-1β, thus, better approximating the physiological 
situation. An additional goal of this study is to investigate the signaling pathways that may 
be involved in any TBT-induced alterations in IL-1β secretion.
MATERIALS AND METHODS
Preparation of PBMCs, MD- PBMCs, and Granulocytes
PBMCs were isolated from Leukocyte filters (PALL- RCPL or RC2D) obtained from the 
Red Cross Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. 
Leukocytes were retrieved from the filters by back-flushing them with an elution medium 
(sterile PBS containing 5 mM disodium EDTA and 2.5% [w/v] sucrose) and collecting the 
eluent. The eluent was layered onto Ficoll-Hypaque (1.077g/mL) and centrifuged at 1200g 
for 30-50 min. Granulocytes and red cells pelleted at the bottom of the tube while the 
PBMCs floated on the Ficoll-Hypaque. Mononuclear cells were collected and washed with 
PBS (500g, 10min). Following washing, the cells were layered on bovine calf serum for 
platelet removal. The cells were then suspended in RPMI-1640 complete medium which 
consisted of RPMI-1640 supplemented with 10% heat-inactivated BCS, 2 mM L-glutamine 
and 50 U penicillin G with 50 μg streptomycin/mL. This preparation constituted PBMCs. 
Monocyte-depleted PBMCs (10-20% CD16+, 10-20 % CD56+, 70-80% CD3+, 3-5% 
CD19+, 2-20% CD14+) were prepared by incubating the cells in glass Petri dishes (150 × 15 
mm) at 37 °C and air/CO2, 19:1 for 1 h. This cell preparation is referred to as MD-PBMCS 
cells. Granulocytes were isolated with the removal of mononuclear and red blood cells as 
described in Kuijpers et al., 2013. Granulocytes were collected and washed with PBS (2500 
rpm, 15min). Red blood cells were lysed with NH4CL isotonic solution (155mM NH4Cl, 
10mM KHCO3, 0.1 mM EDTA) for 10 min. Cells were then washed with PBS and 
centrifuged at 800g for 10 min. The cells were then suspended in RPMI-1640 complete 
medium supplemented with 10% heat-inactivated BCS, 2 mM L-glutamine and 50 U 
penicillin G with 50 μg streptomycin/mL.
Preparation of NK cells
NK cells were prepared from buffy coats (from healthy adult donors) purchased from Key 
Biologics, LLC (Memphis, TN). Highly purified NK cells were prepared using a rosetting 
procedure. RosetteSep human NK cell enrichment antibody cocktail (0.6-0.8 mL) (StemCell 
Technologies, Vancouver, British Columbia, Canada) was added to 45 mL of buffy coat. 
The mixture was incubated for 20 min at room temperature (~ 25° C). Approximately 8 mL 
of the mixture was layered onto 4 mL of Ficoll-Hypaque (1.077 g/mL) (MP Biomedicals, 
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Irvine, CA) and centrifuged at 1200 g for 30-50 min. NK cells were collected and washed 
twice with phosphate buffered saline (PBS) pH 7.2 and stored in complete media 
(RPMI-1640 supplemented with 10% heat-inactivated bovine calf serum (BCS), 2 mM L-
glutamine and 50 U penicillin G with 50 μg streptomycin/ml) at 1 million cells/mL at 37 °C 
and air/CO2, 19:1.
Chemical Preparation
TBT was purchased from Sigma-Aldrich (96%) (St. Louis, MO). Desired concentrations of 
TBT were prepared by dilution of the stock into cell culture media. TBT was a neat 
standard, dissolved initially in deionized water to give a 1 mM solution.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fischer Scientific (Pittsburgh, PA). The stock 
solution for each inhibitor was a 50 mM solution in dimethylsulfoxide (DMSO). Capase-1 
inhibitor II, MEK 1/2 pathway inhibitor (PD98059), p38 inhibitor (SB202190), MEK 1/2 
pathway inhibitor (U0126), and NFκB inhibitor (BAY11-7085) were prepared by dilution of 
the stock solution into cell culture media.
Cell Treatments
NK cells, MD-PBMCs, PBMCs, granulocytes (at a concentration of 1.5 million cells/ mL), 
or PBMCs+granulocytes (at a concentration of 0.75 million cells/mL each) were treated with 
TBT at concentrations of 2.5-200 nM TBT for 24h, 48h, or 6 days. Following the 
incubations, the cells were pelleted and supernatants were collected and stored at -70° C 
until assaying for IL-1β.
For pathway inhibitor experiments, MD-PBMCs (at a concentration of 1.5 million cells/ 
mL) were treated with pathway inhibitors 1h before adding TBT at concentrations of 5, 10, 
25 nM TBT for 24h. Following the incubations, the cells were pelleted and supernatants 
were collected and stored at -70 C until assaying for IL-1β.
Cell Viability
Cell viability was assessed at the beginning and end of each exposure period. Viability was 
determined using the trypan blue exclusion method. Briefly, cells were mixed with trypan 
blue and counted using a hemocytometer. The total number of cells and the total number of 
live cells were determined for both control and treated cells to determine the percent viable 
cells.
IL-1 β Secretion Assay
IL-1 β levels were measured using the BD OptEIA™ Human IL-1 β enzyme-linked 
immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). Briefly, a 96-well 
micro well plate, designed for ELISA (Fisher, Pittsburgh, PA), was coated with a capture 
antibody for IL-1β diluted in coating buffer. The plate was incubated with the capture 
antibody overnight at 4 °C. After incubation, the capture antibody was removed by washing 
the plate three times with wash buffer (PBS and 0.05% Tween-20). Assay diluent (PBS and 
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bovine calf serum) was added to each well (blocking non-specific binding) and incubated at 
room temperature for 1h. The assay diluent was removed by washing the plate three times, 
and the cell supernatants and IL-1β standards were added to the coated plated and incubated 
for 2 h at room temperature. Following this incubation, the plate was thoroughly washed 
five times and then incubated for 1h with a detection antibody to IL-1β which was 
conjugated with horseradish peroxidase. The excess detection antibody was removed by 
washing seven times and a substrate solution was added for 30 min at room temperature to 
produce a colored product. The incubation with the substrate was ended by addition of acid 
and the absorbance was measured at 450 nm on a Thermo Labsystems Multiskan MCC/340 
plate reader (Fisher Scientific).
Statistical Analysis
Statistical analysis of the data was performed by using ANOVA and Student’s t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s 
t test, a p value of less than 0.05 was considered significant.
RESULTS
Viability of NK cells, MD-PBMCs PBMCs, PBMCs+ Granulocytes, and Granulocytes 
exposed to TBT
Table 1 shows the effects of TBT exposures (2.5-200 nM) on the viability of highly purified 
NK cells, MD-PBMCs, PBMCs, PBMCs+granulocytes, and granulocytes. Exposure of NK 
cells to 2.5-100 nM TBT for 24 h had no effect on their viability as compared to the control. 
The highest concentration of TBT (200nM) caused a slight decrease in NK cell viability. 
Exposure to these same concentrations for 48h caused no decrease in viability compared to 
control cells except at the highest concentration of TBT. NK cells exposed to 2.5-50 nM 
TBT for 6 days showed no change in viability as compared to the control; but, 100nM and 
200nM exposures did significantly reduce viability. MD-PBMCs showed a very slight 
decrease in viability with exposure to 200 nM TBT for 24 h. The viability of both MD-
PBMCs and PBMCs was somewhat decreased by exposure to 200 nM TBT for 48 h. After 6 
days both 100 nM and 200 nM TBT caused some decrease in viability of both MD-PBMCs 
and PBMCs. Exposure of PBMCs+granulocytes and granulocytes alone to 2.5-200 nM TBT 
for 24 h had no effect on their viability as compared to the control. Exposure to 200 nM 
TBT for 48h significantly diminished the viability of PBMCs+granulocytes. After 6 days of 
exposure to 200 nM TBT both, PBMCs+granulocytes and granulocytes showed some 
decrease in viability as compared to controls.
Viability of monocyte-depleted PBMCs with pathway inhibitors exposed to TBT
Table 2 shows the effects of TBT exposures (5, 10, 25nM) on the viability of MD-PBMCs 
that were treated with various signaling pathway inhibitors 1 hour prior to adding the 
appropriate concentrations of TBT. No significant changes in viability were seen with any of 
the inhibitors when compared to control cells.
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Effects of TBT Exposure on Secretion of IL-1β by NK cells
Table 3 shows the effects of exposing highly purified NK cells to 0, 2.5, 5, 10, 25, 50, 100 
and 200 nM TBT for 24 h, 48 h, and 6 days on IL-1β secretion from 4 donors tested 
(KB=Key Biologic buffy coat). All donors showed significant decreases in IL-1β when 
exposed to 200 nM TBT for all lengths of exposure. Cells from all 4 donors showed a 
significant increase in IL-1β secretion when exposed to 5, 10, and 25nM TBT. 
Concentrations that caused increases varied from one donor to the next. For instance, the 
cells from donor KB166 treated with 2.5, 5, 10, 25, 50, and 100 nM TBT showed significant 
increases of 1.1, 1.4, 1.7, 1.9, 2.1, and 1.4 fold respectively after 24 h while cells from donor 
KB169 showed significant increases of 1.7, 3.4, 6.7, 6.2, 7.7, and 6.3 fold at these same 
concentrations. When NK cells were exposed to TBT for 48 h, all 4 donors showed 
significant increases in IL-1β secretion at one or more concentration. After 6 d of exposure, 
all donors display significant decreases in IL-1β secretion at 200 nM TBT and increases at 
10 and 25 nM TBT. Figure 1A shows the effects of TBT exposures on IL-1β secretion at 
each of the time points for an individual donor (KB166).
Effects of TBT Exposure on Secretion of IL-1β by MD-PBMCs
The effects of exposures to TBT on secretion of IL-1β from MD-PBMCs after 24 h, 48 h, 
and 6 d from 5 donors (F=filter obtained from the Red Cross) are shown in Table 4. This 
preparation is largely NK cells and T cells. When MD-PBMCs were exposed to TBT for 24 
h there were statistically significant increases in IL-1β secretion induced by TBT for all 
donors at the 25 and 50 nM concentrations with variation in the fold increase among 
different donors (F142 showed 2.0 and 2.1 fold, respectively while F156 showed 4.1 and 5.4 
fold, respectively). Significant decreases in IL-1β secretion were seen at 200 nM TBT for 3 
of the 5 donors after a 24 h exposure. The results seen after a 48 h of exposure to TBT were 
similar to those seen after 24 h. Increases were seen in every donor after a 6 d exposure to 
TBT, however, the number of concentrations that showed significant increases were fewer. 
Figure 1B shows the effects of TBT exposures at each of the lengths of exposure for an 
individual donor (F142).
Effects of TBT Exposure on Secretion of IL-1β by PBMCs
Table 5 summarizes the effects of exposing PBMCs from 5 individual donors to TBT on 
IL-1β secretion (F=filter obtained from the Red Cross). As with NK cells and MD-PBMCs, 
there was rather wide variation in the baseline secretion of IL-1β from one donor to the next 
at each time point. A 24 h exposure to 200 nM TBT, caused a significant decrease (P<0.05) 
in IL-1β secretion in 4 of the 5 donors. Significant increases in IL-1β secretion were seen in 
all donors at 50 nM. Additional concentrations of TBT caused increases in IL-1β secretion 
depending on the donor. For instance, cells from donor F144 treated with 5, 10, 25, 50, and 
100 nM TBT showed significant increases of 1.4, 1.4, 1.6, 2.6, and 2.2 fold, respectively 
while donor F147 treated with 2.5, 5, 10, 25, 50, and 100 nM TBT showed significant 
increases of 1.5, 1.6, 2.7, 2.6, 4.4, and 3.8 fold, respectively. 48 h exposures of PBMCs to 
200 nM TBT caused significant decreases in IL-1β for all donors and significant increases at 
50 nM. After 6 days of exposure, still 4 of the 5 donors showed a significant decrease in 
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IL-1β secretion compared to the control when exposed to 200 nM TBT. Figure 1C shows the 
effects of TBT exposures at each of the lengths of exposure for an individual donor (F144).
Effects of TBT Exposure on Secretion of IL-1β by PBMCs+Granulocytes
Effects of exposing PBMCs+granulocytes to TBT f on IL-1β secretion from the same 5 
donors as for PBMCs alone are shown in Table 6 (F=filter obtained from the Red Cross). 
Like the previous cell types discussed, the concentrations that caused increases and 
decreases in IL-1β secretion varied from one donor to the next in all lengths of exposures as 
did baseline secretion. In contrast to the other cell types, including PBMCs alone, there were 
significant increases of IL-1β noted for 200 nM TBT for 4 of the 5 donors at 24h and 2 of 
the 5 donors at 48h. Cells from donor F144 treated with 10, 25, 50, 100, and 200 nM TBT 
showed fold increases at 1.5, 1.8, 1.5, 1.7, and 1.7, respectively at 24 h and 1.4, 1.5, 1.6, 1.6, 
and 1.2, respectively at 48 h. After 6 days of exposure, control secretion of IL-1β was 
diminished compared to 24 h and 48 h; and the changes in (increases or decreases) of IL-1β 
seen at each concentration of TBT were normally quite small. Figure 1D shows the effects 
of TBT exposures at each of the lengths of exposure for an individual donor (F144).
Effects of TBT Exposure on Secretion of IL-1β by Granulocytes
The effects of exposures to TBT on secretion of IL-1β from granulocytes after 24 h, 48 h, 
and 6 d from the same 5 donors as for PBMCs alone (F=filter obtained from the Red Cross) 
are shown in Table 7. Baseline secretion of IL-1β from granulocytes was quite low, being 
undetectable in 1 donor at 24 h and in all donors by 6 days. When granulocytes were 
exposed to TBT for 24 h there were statistically significant increases in IL-1β secretion 
induced by at least 1 concentration of TBT for 4 of 5 donors. Figure 1E shows the effects of 
TBT exposures at each of the lengths of exposure for an individual donor (F144). Although 
IL-1β secretion was lower for granulocytes than all other cell types tested, there were still 
significant decreases and increases in IL-1β secretion induced by 24 and 48 h exposures to 
TBT.
Effects of TBT Exposure on Secretion of IL-1β by MD-PBMCs treated with Selective 
Signaling Pathway Inhibitors
IL-1β Cleavage Inhibitor (Caspase-1 Inhibitor II)—The effects of exposures to 5, 10, 
and 25 nM TBT on secretion of IL-1β from MD-PBMCs where Caspase-1 had been 
inhibited with Caspase-1 inhibitor II (50 μM) are shown in Table 8. Caspase-1 inhibitor II 
inhibited baseline IL-1β production as this enzyme is required for IL-1β processing. 
However, cells exposed to TBT showed similar fold increases in IL-1β secretion in both the 
presence and absence of the inhibitor. Figure 2A shows the fold increases from a 
representative experiment (F182). There are 1.3, 1.6, and 1.7 fold increases when MD-
PBMCs are exposed to 5, 10, and 25 nM in the absence of the Caspase-1 inhibitor. When the 
inhibitor is present those same TBT exposures are still able to cause 1.3, 1.6, and 2.0 fold 
increases in IL-1β secretion (albeit on a much lower baseline). This same trend was seen in 
all of the donors tested (Table 8). Thus, although the baseline secretion was greatly 
decreased by the presence of the inhibitor, TBT was still able to cause the same magnitude 
of increase in IL-1β secretion as was seen when no inhibitor was present. This indicates that 
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Caspase-1 (needed for IL-1β processing) is not being activated by TBT to increase IL-1β 
secretion, since the magnitude of the TBT-induced increase should have been diminished 
when caspase-1 was inhibited if TBT had been activating this enzyme in order to increase 
IL-1β secretion.
Nuclear Factor kappa B (NFκB) Inhibitor (BAY 11-7085)—The effects of exposures 
to 5, 10, and 25 nM TBT on secretion of IL-1β from MD-PBMCs where NFκB function had 
been inhibited with BAY 11-7085 (1.25 μM) are shown in Table 9. BAY 11-7085 inhibited 
baseline IL-1β production. However, cells exposed to TBT showed no diminution in fold 
increase in IL-1β secretion when the inhibitor was present. In Figure 2B (representative data 
from F218) there are 1.9, 3.0, and 4.8 fold increases when MD-PBMCs are exposed to 5, 10, 
and 25 nM in the absence of NFκB inhibitor. When the inhibitor is present those same TBT 
exposures cause 2.8, 4.9, and 5.3 fold increases in IL-1β secretion. Cells from each of the 
donors tested showed this same pattern (Table 9). Thus, like the Caspase-1, NFκB does not 
seem to be a cellular component that TBT is activating in order to increase the secretion of 
IL-1β from the cells, as the fold increase in secretion is not diminished by the inhibition 
NFκB function.
Mitogen activated protein kinase kinase (MAP2K), MEK, Inhibitor (U0126)—The 
effects of exposures to 5, 10, and 25nM TBT on secretion of IL-1β from MD-PBMCs where 
the mitogen activated protein kinase kinase (MAP2K) for p44/42, MEK, had been inhibited 
with U0126 (50 μM) are shown in Table 10. U0126 had varying effects on baseline IL-1β 
secretion; however, cells exposed to TBT showed a lower fold increase in IL-1β secretion in 
the presence of the inhibitor. In Figure 2C (representative data from F181) we see there are 
2.1, 3.3, and 4.3 fold increases when MD-PBMCs are exposed to 5, 10, and 25 nM TBT in 
the absence of MEK inhibitor. When the inhibitor is present those same TBT exposures are 
able to cause 1.1, 1.3, and 1.2 fold increases in IL-1β secretion. In 3 of the 4 donors tested 
the ability of TBT to increase IL-1β secretion was blocked or significantly decreased when 
the p44/42 pathway was inhibited (Table 10) in the 4th donor the ability of 5 nM TBT to 
increase IL-1β secretion was blocked. This indicates that the p44/42 MAPK pathway is 
being utilized by TBT to lead to the increase in IL-1β secretion.
p38 Inhibitor (SB202190)—The effects of exposures to 5, 10, and 25nM TBT on 
secretion of IL-1β from MD-PBMCs where p38 had been inhibited with SB202190 (25-50 
μM) are shown in Table 11. p38 inhibitor inhibited baseline IL-1β secretion and also 
diminished the ability of TBT to stimulate IL-1β secretion from MD-PBMCs. In Figure 2D 
we see there are 2.5, 3.6, and 5.1 fold increases when MD-PBMCs are exposed to 5, 10, and 
25 nM TBT in the absence of p38 inhibitor. When the inhibitor is present those same TBT 
exposures are able to cause 2.8, 1.5, and 2.6 fold increases in IL-1β secretion. Three of the 4 
donors tested showed that inhibition of the p38 pathway diminished or completely blocked 
the ability of at least one concentration of TBT to simulate IL-1β secretion (Table 11). 
However, 1 donor showed no decrease in TBT-stimulation of IL-1β secretion when the p38 
pathway was inhibited. These results suggest that the p38 pathway may be utilize by TBT to 
stimulate IL-1β secretion, with significant variation among donors.
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IL-1β is an inflammatory cytokine that contributes to chronic inflammation which can 
increase tumor invasiveness (Voronov et al., 2003). TBT is known to contaminate the 
marine and fresh water environment due to common use on boats and ships as an antifouling 
paint (Gipperth, 2009) and levels as high as 261 nM have been found in human blood 
samples (Kannan et al., 1995; Whalen et al., 1999). TBT can decrease the ability of human 
NK cells to destroy tumor cells (Dudimah et al., 2007) and alter the secretion of TNFα and 
IFNγ from immune cells (Hurt et al., 2013; Lawrence et al. 2014). As alterations of levels of 
IL-1β can have profound effects on immune competency as well as tumor development and 
progression (Dinarello, 2009), it is important to determine whether TBT is able to alter the 
secretion of IL-β from immune cells in an ex vivo human model. In this study, increasingly 
reconstituted human immune cell preparations were used (NK cells, MD-PBMCs, PBMCs, 
PBMC+granulocytes, and granulocytes) to determine the effects of TBT on IL-β secretion. 
Additionally experiments to identify signaling pathways involved in TBT-induced 
alterations of IL-1β levels were also conducted.
Baseline secretion of IL-1β varied among the different cell preparations. NK cells and MD-
PBMCs showed very similar baseline secretions. The presence of monocytes caused a 
greater baseline secretion for PBMCs. This is expected due to the fact that monocytes (along 
with macrophages) are the major IL-1β secreting cell type (Dinarello, 2009). Granulocytes 
alone showed very low baseline secretion of IL-1β. Granulocytes have been shown by others 
to be capable of secreting IL-1β (Guma et al., 2009). The concentration at which TBT 
caused the maximum fold increase in IL-β from each of the different cell types (after 24 h of 
exposure) varied among the donors. The average of the maximum fold increase (from each 
donor, 4 donors) for pure NK cells was 3.2 fold (this ranged from 1.3 fold to 7.8 fold over 
the range of 2.5-100 nM). For MD-PBMCs, the average of the greatest fold increase (5 
donors) was 11.2 fold (ranging from 1.8-33 fold over 2.5-100 nM depending on the donor) 
and for PBMCs the value was 2.6 fold (again from 5 donors) increases ranged from1.4-4.4 
fold. PBMCs plus granulocytes showed an average highest increase in TBT-stimulated 
IL-1β secretion of 4.7 fold (same 5 donors as the PBMCs alone) with at range of 1.3-16 fold. 
While the average of the maximum increase is higher from PBMCs plus granulocytes than 
from PBMCs alone this is entirely due to the highest value being much greater in one donor 
(16 fold) than was seen in the PBMCs. All other donors showed similar maximum secretion 
values in both the PBMCs alone and the PBMCs plus granulocytes. Granulocytes alone 
exhibited an average maximum increase of 3.8 fold (ranging from 2-12 fold). However, as 
mentioned above, the overall level of secretion was very small from this cell preparation. 
These results indicate that TBT has the greatest ability to increase IL-1β secretion from the 
MD-PBMCs (a preparation that is predominantly T and NK lymphocytes). This suggests 
that in the in vivo setting that those areas where there is an enrichment of T and NK 
lymphocytes may be more susceptible to potential dysregulation by exposures to TBT, such 
as the tumor microenvironment (Whiteside, 2008). The fact that there is greater average 
secretion stimulated in the MD-PBMCs suggests that there may be TBT-stimulated secretion 
of another factor when T cells are the dominant cell type that stimulates IL-1β secretion 
from the T cells and or other cell types present in this cell preparation. T cells are major 
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producers of IFNγ and IFNγ has been shown to increase secretion of IL-1β from human 
immune cells (Masters et al., 2010). Recently, we have shown that TBT greatly increases the 
secretion of IFNγ from MD-PBMCs over the range of 2.5-100 nM after 24 h (Lawrence et 
al., 2014) and this IFNγ may then lead to the increase in IL-1β seen in this particular cell 
preparation. 200 nM TBT normally blocked or decreased IL-1β secretion from NK cells, 
MD-PBMCs and PBMCs, while increases in IL-1β secretion were seen with TBT 
concentrations ranging from 2.5 to 100 nM (depending on the donor). These data suggest 
that TBT is affecting similar pathways in NK cells, T cells, and monocytes. However, when 
granulocytes are present in the reconstituted cell preparation (PBMCs + granulocytes) 
exposure to 200 nM TBT caused a significant increase in IL-1β production in 4 of the 5 
donors. This is in stark contrast to the effects of 200 nM TBT on PBMCs, which caused a 
large decrease in IL-1β secretion in these same donors. The effects of 200 nM TBT 
exposures on granulocytes (alone) from these donors indicate that granulocytes were not 
responsible for the increased IL-1β secretion seen at 200 nM TBT in the PBMC+ 
granulocyte preparation. Interestingly, the effects of lower concentrations of TBT on 
granulocytes showed a similar pattern as seen with the other cell preparations (increased 
IL-1β secretion) albeit on a much lower baseline. This suggests that granulocytes are able to 
reverse the negative effects of 200 nM on IL-1β secretion from PBMCs, but do not 
appreciably alter the effects of TBT at lower concentrations. One explanation for this effect 
may be that, due to TBT binding to the granulocytes, a lower effective concentration of TBT 
is seen by the PBMCs. As the data shows, a small shift in the effective concentration of TBT 
could take it from a level that is inhibitory to one that is stimulatory of IL-1β secretion. It 
might be expected that TBT will bind to components within the cell with varying affinity. At 
higher concentrations of TBT such as 200 nM you would expect that the largest number of 
components capable of interacting with TBT would do so and that this would result in 
multiple (and possibly competing) effects including toxic effects that lead to an increased 
level of cell death over time (as is seen in the viability data). As the concentrations decreases 
(such as at 10 or 25 nM) TBT will interact with far fewer components and may show a 
completely opposite effect (from that seen at higher concentrations) depending on the nature 
of the component(s) that it influences. This appears to be the case with respect to IL-1β 
secretion. At 200 nM TBT is inhibitory to this process, while at 10 nM it is stimulatory. 
Overall, the data indicates that TBT-induced alterations of IL-1β secretion from human 
immune cells may be a significant consequence of TBT exposures and that TBT may 
potentially affect immune competence and cancer invasiveness.
Several signaling pathways are involved in the production/secretion of IL-1β from immune 
cells. They include caspase 1, NFκB, and MAPKs (p44/42 and p38). We found that 
inhibition of caspase-1 did not affect TBT-induced secretion, indicating that while this 
enzyme is critical for secretion of IL-1β from immune cells it does not seem to be necessary 
for TBT-induced increases in IL-1β secretion. Thus, it is apparently not one of the cellular 
components that is bound by TBT at concentrations of 5-25 nM. NFκB is a signaling 
component that is required for the transcription of several cytokine genes including the 
IL-1β gene (Cogswell et al., 1994; Perez et al., 1997; Scheibel et al., 2010). The results of 
this study indicate that, like the caspase-1 pathway, the NFκB pathway is also not a target of 
TBT at those concentrations where TBT causes increases in IL-1β secretion. p44/42 MAP 
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kinase (ERK 1 and ERK 2) plays an important role in cell growth regulation (Cowley et al., 
1994; Hunter et al., 1995; Marshall, 1995). Activation of p44/42 leads to activation of the 
AP-1 transcription activator (composed of fos and jun genes) leading to an increase of IL-1β 
transcription (Glauser et al., 2007). When the p44/42 pathway was inhibited by a MEK 
inhibitor, TBT-induced increases in IL-1β secretion were blocked. These results suggest that 
TBT causes p44/42 pathway activation which then results in increased IL-1β synthesis and 
secretion. Previous studies have shown that TBT is capable of activating p44/42 in highly 
purified NK cells (Abraha et al., 2008). The current results indicate a need to examine 
p44/42 activation by TBT in MD-PBMCs. The MAPK, p38, has also been shown to regulate 
the production of cytokines (Davis et al., 1995; Young et al., 1993) including IL-1β by 
activation of C/EBPβ/NFIL-6 transcription activator (Baldassare et al., 1999). Inhibition of 
the p38 pathway diminished TBT-induced IL-1β secretion in 3 of the 4 donors tested. This 
suggests that a component(s) of the p38 may also be a target of lower concentrations of TBT 
leading to increased IL-1β secretion. Figure 3 summarizes the pathways that may be 
involved in regulating IL-1β synthesis and secretion.
Sterile inflammation is a term used to describe inflammation occurring in the absence of a 
microorganism (Chen and Nunez, 2010). Chemical exposure could result in sterile 
inflammation by its ability to induce the production of pro-inflammatory cytokines such as 
IL-1β. TBT may have this potential. Our ex-vivo results indicate that at low exposure 
concentrations TBT increases levels of IFNγ, TNFα (Lawrence et al., 2014; Hurt et al., 
2013), and IL-1β. Concentrations of TBT as low as 2.5 nM were able to increase IL-1β 
secretion and we know from past studies a majority of donors tested had blood levels that 
exceeded 2.5 nM (Kannan et al., 1999; Whalen et al., 1999). If TBT were to have similar 
effects in vivo, then exposure may have the potential to cause chronic inflammation, which 
has a host of negative consequences including, exacerbation of symptoms in multiple 
sclerosis and rheumatoid arthritis (Lucas and Hohlfeld, 1995; Choy and Panayi, 2001) as 
well as enhanced tumor development and progression (Lewis and Varghese, 2006).
The current study indicates that TBT alters IL-1β secretion from increasingly reconstituted 
preparations of human immune cells. The highest concentration of TBT tested blocked 
secretion of IL-1β from highly purified NK cells, MD-PBMCs, and PBMCs; however, when 
granulocytes were added to PBMCs, 200 nM TBT now increased IL-1β secretion. Lower 
concentrations of TBT elevated secretion of IL-1β from NK cells, MD-PBMCs, PBMCs, 
and granulocytes. This study also indicates that components of the p44/42 and possibly p38 
MAPK pathways are targets of TBT. The fact that these pathways are both known to 
regulate IL-1β production (Baldassare et al., 1999; Glauser et al., 2007), and are needed for 
the TBT-induced secretion of IL-1β suggests that increased IL-1β transcription and 
translation are a requirement for this effect.
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Effects of 24 h, 48 h and 6 day exposures to TBT on IL-1β secretion from highly purified 
human NK cells, monocyte-depleted PBMCs, PBMCs, PBMCs plus granulocytes, and 
granulocytes in individual donors. A) NK cells exposed to 0-200 nM TBT (donor KB166). 
B) Monocyte-depleted PBMCs exposed to 0-200 nM TBT (donor F142). C) PBMCs 
exposed to 0-200 nM TBT (donor F144). D) PBMCs plus granulocytes exposed to 0-200 
nM TBT (donor F144). E) Granulocytes exposed to 0-200 nM TBT (donor F144).
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Effects of 24 h exposure to 5, 10, and 25 nM TBT on IL-1β secretion from monocyte-
depleted PBMCs treated with selective pathway component inhibitors in individual donors. 
A) IL-1β Cleavage Inhibitor (Caspase-1 Inhibitor II) (donor F182). B) NFκB Inhibitor 
(BAY 11-7085) (donor F218). C) MEK ½(p44/42) Inhibitor (U0126) (donor F181). D) P38 
Inhibitor (SB202190) (donor F183).
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Signaling pathways regulating IL-1β secretion.
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Table 3
Effects of 24 h, 48 h, 6 day exposures to TBT on IL-1β secretion from highly purified human NKs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM KB166 KB167 KB168 KB169
0 761±14 294±5 1623±46 71±9
2.5 869±44* 455±82 2034±84* 125±13*
5 1063±97* 424±10* 1943±59* 245±11*
10 1326±82* 463±4* 1730±11* 474±21*
25 1444±47* 439±78 2135±49* 443±24*
50 1609±20* 358±15* 1621±59 551±10*
100 1065±22* 99±101 362±6* 446±9*
200 0±10* 0±26* 0±2* 0±10*
48 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM KB166 KB167 KB168 KB169
0 1206±8 402±10 2101±322 281±10
2.5 1161±96 383±16 2791±125* 327±39
5 1358±67 379±31 2624±36 909±50*
10 1740±82* 430±24 2647±78 1302±47*
25 1937±91* 444±6* 2427±156 1578±75*
50 2025±27* 435±28 2039±31 1726±48*
100 1475±32* 18±6* 510±10* 801±51*
200 61±52* 0±11* 0±11* 0±5*
6day Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM KB166 KB167 KB168 KB169
0 883±30 101±11 1748±24 490±18
2.5 535±42* 221.±33* 1821±106 389±29*
5 773±13* 225±49* 2065±32* 438±16*
10 1062±62* 180±33* 1968±41* 1051±23*
25 1124±69* 213±7* 1960±67* 954±24*
50 1281±40* 129±9* 1623±64 1026±31*
100 1042±18* 0±2* 250±11* 390±8*
200 32±3* 0±14* 0±4* 0±16*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05
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Table 8
Effects of IL-1β Cleavage Inhibition (Caspase-1 Inhibitor II (CI)) on TBT-induced IL-1β secretion from MD-
PBMCs
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM F181 F182 F183 F185
0 853±23 4401±220 1416±147 7634±426
0 + CI 44±7 1029±38 215±8 2544±174
5 1376±72* 5725±513* 2484±147* 8148±394
5 + CI 152±65 1324±110** 333±35** 2434±190
10 1770±68* 6928±268* 3712±156* 7838±308
10 + CI 227±56** 1599±121** 575±82** 2846±36
25 2347±202* 7575±447* 5041±154* 10049±183*
25 + CI 246±12** 2087±105** 1018±35** 3998±194**
Values are mean±S.D. of triplicate determinations.
*
indicates a significant increase compared to no TBT (0), p<0.05;
**
indicates a significant increase compared to no TBT+inhibitor (0+CI), p<0.05
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Table 9
Effects of NFκB Inhibition (BAY 11-7085 (BAY)) on TBT-induced IL-1β secretion from MD-PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM F218 F219 F225
0 805±64 754±54 520±151
0 + BAY 152±37 234±28 190±21
5 1551±57* 1749±141* 753±42
5 + BAY 420±92** 923±254** 1042±212**
10 2434±239* 3185±96* 1921±473*
10 + BAY 739±149** 1523±266** 1476±331**
25 3838±120* 2647±132* 1616±121*
25 + BAY 805±29** 1278±213** 1476±25**
Values are mean±S.D. of triplicate determinations.
*
indicates a significant increase compared to no TBT (0), p<0.05;
**
indicates a significant increase compared to no TBT+inhibitor (0+BAY), p<0.05
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Table 10
Effects of p44/42 Pathway Inhibition (U0126 (U)) on TBT-induced IL-1β secretion from MD-PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM F181 F182 F183 F185
0 643±96 2778±121 1519±68 6310±100
0 + U 768±102 4969±96 1437±116 2836±106
5 1377±50* 4544±233* 2836±134* 7608±342*
5 + U 830±104 5280±309 3044±540** 3042±384
10 2117±74* 6100±237* 4279±205* 8560±166*
10 + U 981±27 5406±344 2246±314** 5187±228**
25 2783±9* 7000±149* 5771±185* 8836±186*
25 + U 955±18 3755±392 2574±130** 6691±122**
Values are mean±S.D. of triplicate determinations.
*
indicates a significant increase compared to no TBT (0, p<0.05);
**
indicates a significant increase compared to no TBT+inhibitor (0+U), p<0.05
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Table 11
Effects of p38 Inhibition (SB202190 (SB)) on TBT-induced IL-1β secretion from MD-PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[TBT] nM F183 F185 F236 F237
0 1459±119 6153±322 2537±180 968±113
0 + SB 1493±96 1249±73 483±62 541±29
5 3640±110* 6711±201 4365±369* 1280±95*
5 + SB 4176±442** 1454±54** 1618±238** 1510±53**
10 5222±158* 9791±250* 4356±513* 2289±103*
10 + SB 2199±87** 872±50 1477±90** 1479±19**
25 7504±204* 7679±30* 6807±629* 4348±71*
25 + SB 3871±200** 1048±12 1701±157** 1065±22**
Values are mean±S.D. of triplicate determinations.
*
indicates a significant increase compared to no TBT (0), p<0.05;
**
indicates a significant increase compared to no TBT+inhibitor (0+SB), p<0.05
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